A year after Tysabri was reintroduced for multiple sclerosis, its manufacturers say that 14,000 patients are now taking the drug. Tysabri, once viewed as a major breakthrough for MS, was pulled after the drug was linked to a risk of PML, a viral infection of the brain. Elan and Biogen Idec make the drug.
- read the report from Finfacts
FDA allows Tysabri back on market. Report
FDA allows limited trial of Tysabri. Report
Tysabri may spur better risk/reward evaluation. Report
Elan hammered on reported case of PML. Report